Li Bo, Lu Chang, Liu Yibo, Wang Xiaodong, Fu Haiqi, Li Changyi, Sun Mingjuan, Zhang Yajun, Li Minhui
Inner Mongolia Medical University, Hohhot, 010010, China.
Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, 010050, China.
Heliyon. 2023 Dec 10;10(1):e23474. doi: 10.1016/j.heliyon.2023.e23474. eCollection 2024 Jan 15.
Hypertension has become a part of the lives of many people worldwide. With the development, an increasing number of people have begun to control their hypertension through products of medicine food homology, such as Buyang Huanwu Decoction (BYHWD). However, there has been no objective review of the regulation of hypertension by BYHWD.
As of 9 October 2023, this review made a detailed search of nine databases to look for random controlled trials (RCTs) focused on the use of BYHWD for treating hypertension. This was followed by network pharmacological analysis, and molecular docking assessment using AutoDockTools to explore the mode of action.
BYHWD was effective in reducing SBP (MD: 0.767; 95 % CI: 0.629, 0.905; = 0.000), DBP (MD: 0.427; 95 % CI: 0.292, 0.561; = 0.000), 24h SBP (MD: 0.665; 95 % CI: 0.368, 0.962; = 0.000), 24h DBP (MD: 0.547; 95 % CI: 0.318, 0.777; = 0.000), dSBP (MD: 0.625; 95 % CI: 0.395, 0.855; = 0.000), dDBP (MD: 0.632; 95 % CI: 0.401, 0.862; = 0.000), nSBP (MD: 0.859; 95 % CI: 0.340, 1.377; = 0.001), nDBP (MD: 0.704; 95 % CI: 0.297, 1.112; = 0.001), pv (MD: 1.311; 95 % CI: 0.363, 2.259; = 0.007) and NIHSS (MD: 1.149; 95 % CI: 0.100, 2.199; = 0.032), and elevating CER (OR = 2.848; 95 % CI: 1.388, 5.843; = 0.004). However, BYHWD did not significantly reduce HCY, and there was no significant difference in the incidence of AE. In terms of the mechanism of action, the main active ingredient of BYHWD is quercetin, and the core targets are AKT1, MMP9, and others. Molecular docking also showed that quercetin mainly interacts with the amino acid residue CYS-28 of MMP2. Second, the KEGG analysis showed that BYHWD mainly act on HIF-1, Apelin, and cGMP-PKG signalling pathways, and GO analysis showed that it related to the apical part of the cell, circulatory system processes, and nuclear receptor activity. BYHWD can lowered blood pressure, reduced plasma viscosity, and restored neurological function with good tolerability, and had no significant effect on HCY levels. This study further demonstrated that quercetin is the main active ingredient of BYHWD that acts via the AKT1 and HIF-1 signalling pathways. These results provide new guidance for people's dietary choices by the general public.
高血压已成为全球许多人生活的一部分。随着发展,越来越多的人开始通过药食同源产品,如补阳还五汤(BYHWD)来控制高血压。然而,尚未有对补阳还五汤调节高血压的客观综述。
截至2023年10月9日,本综述对九个数据库进行了详细检索,以寻找专注于使用补阳还五汤治疗高血压的随机对照试验(RCT)。随后进行网络药理学分析,并使用AutoDockTools进行分子对接评估,以探索其作用模式。
补阳还五汤在降低收缩压(MD:0.767;95%CI:0.629,0.905;P = 0.000)、舒张压(MD:0.427;95%CI:0.292,0.561;P = 0.000)、24小时收缩压(MD:0.665;95%CI:0.368,0.962;P = 0.000)、24小时舒张压(MD:0.547;95%CI:0.318,0.777;P = 0.000)、日间收缩压(MD:0.625;95%CI:0.395,0.855;P = 0.000)、日间舒张压(MD:0.632;95%CI:0.401,0.862;P = 0.000)、夜间收缩压(MD:0.859;95%CI:0.340,1.377;P = 0.001)、夜间舒张压(MD:0.704;95%CI:0.297,1.112;P = 0.001)、血浆黏度(MD:1.311;95%CI:0.363,2.259;P = 0.007)和美国国立卫生研究院卒中量表(NIHSS)评分(MD:1.149;95%CI:0.100,2.199;P = 0.032)以及升高脑钠肽(OR = 2.848;95%CI:1.388,5.843;P = 0.004)方面有效。然而,补阳还五汤并未显著降低同型半胱氨酸水平,且不良事件发生率无显著差异。在作用机制方面,补阳还五汤的主要活性成分是槲皮素,核心靶点是AKT1、基质金属蛋白酶9等。分子对接还表明,槲皮素主要与基质金属蛋白酶2的氨基酸残基CYS - 28相互作用。其次,KEGG分析表明,补阳还五汤主要作用于缺氧诱导因子 - 1、阿片肽和环磷酸鸟苷 - 蛋白激酶G信号通路,GO分析表明它与细胞顶端、循环系统过程和核受体活性有关。补阳还五汤可降低血压、降低血浆黏度并恢复神经功能,耐受性良好,且对同型半胱氨酸水平无显著影响。本研究进一步证明,槲皮素是补阳还五汤通过AKT1和缺氧诱导因子 - 1信号通路发挥作用的主要活性成分。这些结果为公众的饮食选择提供了新的指导。